PW Medtech Group Ltd. (HK:1358) has released an update.
PW Medtech Group Ltd. has announced the proposal to spin off its subsidiary, Sichuan Ruijian Medical, without issuing new shares, maintaining its status as a subsidiary post-quotation. The move aims to capitalize on the growing blood purification device market in China, improve Sichuan Ruijian Medical’s market position, and provide it with direct access to domestic capital markets. Shareholders are advised to exercise caution as the spin-off is still subject to market conditions and regulatory approvals.
For further insights into HK:1358 stock, check out TipRanks’ Stock Analysis page.
